A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.

Trial Profile

A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 May 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Mitoxantrone; Prednisone
  • Indications Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms COMET-2
  • Sponsors Exelixis
  • Most Recent Events

    • 10 Feb 2018 Results (n=1147) of retrospective analysis of a combined dataset of COMET-1 and COMET-2 trials identifying a benefit in subsets of patients based on prognostic risk factors presented at the 2018 Genitourinary Cancers Symposium
    • 19 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
    • 01 Dec 2014 Results published in an Exelixis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top